SERO Serologicals (MM)

Serologicals Corporation (NASDAQ:SERO), announced today that the United States Patent and Trademark Office awarded, on September 27, 2005, patent no. 6,949,361 with respect to its recently acquired artificial ubiquitous chromatin opening element (UCOE) polynucleotide and related vectors. Serologicals acquired the UCOE gene expression technology, which includes fifty-five (55) issued and pending patents, on September 30, 2005. UCOEs improve the yield, consistency and stability of protein production in cultured mammalian cells, allowing simpler and quicker generation of proteins at small scale for drug discovery and research, as well as quicker and easier isolation of stable, highly productive cell lines suitable for larger-scale manufacture of protein therapeutics. The UCOE that is the subject of this patent family is especially significant because it does not occur in nature. David A. Dodd, President and Chief Executive Officer of Serologicals Corporation, commented on the receipt of the patent, stating, "Our recent acquisition of the UCOE technology exemplifies our ongoing focus on developing and acquiring innovative technologies that ensure we remain the leader in Bioprocessing technologies. Our research and development groups will capitalize on this important technology for the benefit of our customers and will introduce it into our own manufacturing processes. As a result of having applied these technologies, we anticipate supporting our customer's efforts to produce more consistent products with more efficient bioproduction systems." Dennis W. Harris, Vice President, Research & Development, Business Development and Chief Scientific Officer for Serologicals Corporation, will be in charge of inquiries about possible out-licensing opportunities using this patented technology. He can be reached at 408-779-4533, extension 248. Celliance(TM) offers an expanding array of bioprocessing products and services including diagnostic products and cell culture media supplements. Key products include EX-CYTE(R), the largest selling cell growth supplement, Probumin(TM), a proprietary line of bovine serum albumin and Incelligent(TM), the Company's recombinant human insulin. It is also the world's leading provider of monoclonal antibodies for the blood typing industry. Celliance(TM) is a Serologicals company based in Atlanta, GA. Serologicals Corporation (NASDAQ:SERO), headquartered in Atlanta, Georgia, is a global provider of biological products, enabling technologies and services to a diverse customer base that includes major life science companies and leading research institutions. Our customers use our products, technologies and services in a wide variety of their activities, including basic research, drug discovery, diagnosis and biomanufacturing. Our products, technologies and services are essential tools for research in key disciplines, including neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and molecular biology. In addition, the Company is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA. For more information, please visit our website: www.serologicals.com and www.celliancecorp.com. This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" and similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. Serologicals is a registered trademark of Serologicals Royalty Company.